Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : IPSEN PHARMA SAS
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY
The primary study objective is to assess the long term safety of repeated treatments with Dysport used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
Phase III, multicentre study assesssing the long term safety and and efficay of repeated treatments with Dysport in the treatment of leg spasticity in adult patients with hemiparesis
The primary study objective is to assess the long term safety of Dysport in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated Treatment Cycles.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a Guided Self Rehabilitation Contract in Adult Subjects with Spastic Hemiparesis
The primary objective is to assess the responder rate as defined by the improvement of composite active range of motion (AROM) in the primary targeted limb, either upper limb (UL) or lower limb (LL), ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma, as assessed by evaluating the change in pituit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY
The primary study objective will be to assess the efficacy of Dysport compared to placebo at Week 4 on the mean change from baseline in ankle joint hypertonicity in children with dynamic equinus foot ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
Clinical research in patients with acromegaly for the assessment of test product BIM23B065, that will be given to them as repeated subcutaneous injection
To assess the pharmacodynamics of repeated administration of BIM23B065 in reducing growth hormone (GH) in subjects with acromegaly
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of lower limb spasticity in adult subjects with spastic hemiparesis due to stroke or traumatic brain injury
The primary study objective is to assess the efficacy of Dysport compared to placebo at Week 4 on the change from baseline in the gastrocnemius-soleus complex (GSC) muscle tone (knee extended) in hemi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide Uno studio interventistico non terapeutico destinato a valutare l’attivazione ex vivo dei basofili in risposta alle preparazioni di taspoglutide
To assess the occurrence of positive reaction (basophil activation signal) to various taspoglutide formulations (including taspoglutide used in Phase III clinical trials, extra-pure (EP) taspoglutid...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY
To model the PCA3 score change at 6 months post-treatment using a multivariate linear model and the following variables outcomes at baseline: age, Prostate Specific Antigen (PSA), clinical stage (TNM)...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
IPSEN PHARMA SAS
MAJ Il y a 5 ans
A study to assess efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoear in adults
The primary objective of the study is to demonstrate that diosmectite efficacy is superior to placebo regarding the time to recovery of an acute diarrhoea episode presumed of infectious origin in adul...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations